PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26543364-14 2015 CONCLUSION: The MTX-LNC were better than the MTX solution at reducing proinflammatory cytokines and T-cell-derived cytokines such as interferon-gamma and interleukin-17A. Methotrexate 16-19 interleukin 17A Homo sapiens 154-169 32516443-11 2021 Methotrexate treatment helps to decrease IL-9, IL-17 and VEGF levels, thereby limiting the disease progression and improving quality of life in psoriasis. Methotrexate 0-12 interleukin 17A Homo sapiens 47-52 29572822-9 2018 Moreover, MTX could significantly restore the immunosuppressive function of IL-17-secreting Tregs. Methotrexate 10-13 interleukin 17A Homo sapiens 76-81 28143790-10 2017 IL17A-152 G/A polymorphism was associated with an enhanced response to biologic and MTX treatment. Methotrexate 84-87 interleukin 17A Homo sapiens 0-5 32300908-11 2020 IL-17 was higher in subjects with fewer missing teeth if the following criteria were fulfilled: shorter prednisolone (< 5 mg) and methotrexate therapy, more swollen joints, longer morning stiffness. Methotrexate 130-142 interleukin 17A Homo sapiens 0-5 31606265-5 2020 RESULTS: Compared with cyclosporine and methotrexate, anti-IL-17A treatment resulted in a greater increase in GLS at 4 and 12 months after treatment (10% and 14% with anti-IL-17A vs 2% and 2% with cyclosporine vs 4% and 4% with methotrexate, respectively), GLSR, GLSR at early diastole (45% and 41% vs 5% and 4% vs 7% and 9%, respectively), and LV twisting (32% and 28% vs 6% and 8% vs 7% and 6%, respectively) (P < 0.05). Methotrexate 228-240 interleukin 17A Homo sapiens 59-65 30479197-12 2018 CONCLUSIONS: Our findings suggest that initial targeted treatment with IL-17 inhibitors is the most effective treatment strategy for plaque psoriasis patients who have failed methotrexate and phototherapy. Methotrexate 175-187 interleukin 17A Homo sapiens 71-76 24792332-6 2015 We suggest that the treatment with MTX and MP could ameliorate RA disease activity by normalizing the distribution/imbalance of Th17/Treg and indicate a new regulatory role of IL-17(+) cells in RA patients. Methotrexate 35-38 interleukin 17A Homo sapiens 176-181 26273599-5 2015 Markedly decreased levels of IL-17, retinoid-related orphan receptor C (RORc), and MMP-3 mRNA expression were also observed in IL-6-induced RASFs in the presence of T-614 or MTX compared with those in its absence. Methotrexate 174-177 interleukin 17A Homo sapiens 29-34 19847432-0 2010 The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Methotrexate 30-42 interleukin 17A Homo sapiens 82-87 22802109-6 2012 RESULTS: Combined administration of ETN/MTX significantly inhibited the proliferation of T lymphocytes, decreased serum IL-6, TNF-alpha, IL-1beta, RANKL and macrophage supernatant IL-17, LT-alpha, increased serum IFN-gamma and macrophage supernatant IL-10. Methotrexate 40-43 interleukin 17A Homo sapiens 180-185 25790671-0 2015 [Effect of Sanhuang Yilong Decoction combined MTX on the expression of serum IL-1, IL-6, and IL-17 in rheumatoid arthritis patients of accumulated dampness-heat syndrome]. Methotrexate 46-49 interleukin 17A Homo sapiens 93-98 25790671-1 2015 OBJECTIVE: To study the effect of bitter-cold herbs easing dampness method (BCHEDM) plus Sanhuang Yilong Decoction (SYD) combined with methotrexate (MTX) on expression levels of interleukin-1 (IL-1), IL-6, and IL-17 in rheumatoid arthritis (RA) patients of accumulated dampness-heat syndrome (ADHS). Methotrexate 149-152 interleukin 17A Homo sapiens 210-215 25790671-9 2015 CONCLUSION: SYD combined MTX could play roles of improving inflammatory indices within 2 weeks, and inhibiting the expression of IL-1, IL-6, and IL-17 within 4 weeks. Methotrexate 25-28 interleukin 17A Homo sapiens 145-150 24489536-4 2013 To compare the effect of narrow band ultraviolet B (NB-UVB) and methotrexate (MTX) therapy on serum levels of IL-17 and IL-23 in psoriatic patients. Methotrexate 64-76 interleukin 17A Homo sapiens 110-115 24489536-4 2013 To compare the effect of narrow band ultraviolet B (NB-UVB) and methotrexate (MTX) therapy on serum levels of IL-17 and IL-23 in psoriatic patients. Methotrexate 78-81 interleukin 17A Homo sapiens 110-115 21691744-0 2012 Methotrexate attenuates the Th17/IL-17 levels in peripheral blood mononuclear cells from healthy individuals and RA patients. Methotrexate 0-12 interleukin 17A Homo sapiens 33-38 21691744-6 2012 The augmentation of IL-17 at the mRNA and protein levels was significantly inhibited when PBMC cultures were preincubated with MTX. Methotrexate 127-130 interleukin 17A Homo sapiens 20-25 21691744-7 2012 Compared with PBMCs of healthy donors, PBMCs of RA patients produced higher levels of IL-17, and this increase in IL-17 levels was more inhibited by MTX pretreatment. Methotrexate 149-152 interleukin 17A Homo sapiens 86-91 21691744-7 2012 Compared with PBMCs of healthy donors, PBMCs of RA patients produced higher levels of IL-17, and this increase in IL-17 levels was more inhibited by MTX pretreatment. Methotrexate 149-152 interleukin 17A Homo sapiens 114-119 21691744-8 2012 MTX inhibited IL-17 at the mRNA level in a dose-dependent manner, but not at the protein level, in both PBMCs of healthy donors and RA patients. Methotrexate 0-3 interleukin 17A Homo sapiens 14-19 21691744-10 2012 MTX dose dependently suppressed the production of IL-17 at the mRNA level by PBMCs from healthy donors and RA patients. Methotrexate 0-3 interleukin 17A Homo sapiens 50-55 21691744-11 2012 Suppression of IL-17 by MTX may contribute to its potent anti-inflammatory role in RA therapy. Methotrexate 24-27 interleukin 17A Homo sapiens 15-20 21943782-3 2011 Compared with the placebo plus MTX group, serum levels of IL-17, IFN-gamma, IL-21 and IL-1beta significantly decreased, the percentages of Th17 cells and Th1 cells were lower and the percentage of Treg cells was higher after receiving Anakinra combined with MTX treatment. Methotrexate 31-34 interleukin 17A Homo sapiens 58-63 19847432-1 2010 Objective of the study is to assess the effects of adalimumab and MTX therapy on peripheral Th17 cells and IL-17/IL-6 secretion in RA patients. Methotrexate 66-69 interleukin 17A Homo sapiens 107-112 20601897-8 2010 Only in the infliximab + MTX group that the frequency of T(H)17 cells and concentration of IL-17 decreased. Methotrexate 25-28 interleukin 17A Homo sapiens 91-96 11966773-10 2002 Pharmacological drugs used in therapy of RA, such as cyclosporin and methotrexate, induced a fourfold increase of IL-17R mRNA expression and augmented the IL-17-stimulated IL-8 expression. Methotrexate 69-81 interleukin 17A Homo sapiens 114-119